Standout Papers

Talazoparib versus chemotherapy in patients w... 2013 2026 2017 2021 572
  1. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial (2020)
    Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology
  2. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial (2013)
    Ann‐Lii Cheng, Yoon‐Koo Kang et al. Journal of Clinical Oncology

Immediate Impact

4 from Science/Nature 106 standout
Sub-graph 1 of 13

Citing Papers

Targeting immunogenic cell stress and death for cancer therapy
2024 Standout
Arginine reprograms metabolism in liver cancer via RBM39
2023 Standout
36 intermediate papers

Works of Silvana Lanzalone being referenced

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013 Standout
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
2009
and 4 more

Author Peers

Author Last Decade Papers Cites
Silvana Lanzalone 850 729 248 811 35 1.9k
Belinda Cancilla 1131 657 170 342 38 2.7k
Francesco Galimi 1148 437 83 737 35 2.4k
Camilla Pilati 1057 283 333 529 32 2.6k
Elisa Sensi 1472 566 225 410 44 2.3k
Massimo Lopez 1563 586 204 269 59 2.2k
Zhaoshi Zeng 1285 391 177 411 37 2.5k
Cristiana Lupi 1628 611 183 408 34 2.7k
Jane Robertson 1263 500 207 220 56 2.0k
Sara Toffanin 505 257 102 871 18 2.3k
Silvia Benvenuti 1586 910 77 420 39 2.6k

All Works

Loading papers...

Rankless by CCL
2026